/EMMLF

EMMLF Stock - OKYO Pharma Limited

Q: What is the analyst price target for EMMLF?

Analyst price target information is not currently available for EMMLF.

Q: What is EMMLF's market cap?

Market capitalization information is not currently available for EMMLF.

Healthcare|Biotechnology|OTC

$0.01+0.00%

+$0.00 (+0.00%) • May 12

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.02

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EMMLF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.06

52W High$0.89

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-2,563	$-3,866	$-3,797	$-2,423	$-13,086
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-7,188,875	$-15,694,549	$-13,087,270	$-6,231,000	$-4,133,349
Net Income	$-4,706,292	$-16,825,461	$-13,272,000	$-5,431,000	$-3,354,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.12	$-0.00	$-0.60	$-0.36	$-0.32

Company Overview

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Visit Website